The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia

Author(s): Nikolaos Pitsikas

Journal Name: Current Medicinal Chemistry

Volume 23 , Issue 24 , 2016

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Close to 1% of the world population suffer from schizophrenia. Current medications for this chronic mental disorder have greatly improved treatment over the last half century or more, but, the newer atypical antipsychotics have proven to be disappointing, and enormous challenges remain. The negative symptoms and cognitive dysfunction in schizophrenia which greatly affect overall morbidity call for better treatments. Nitric oxide (NO), an intra- and inter-cellular messenger in the brain, is involved in the pathogenesis of schizophrenia, so excessive NO production might contribute to the pathology. This implies that it might be useful to reduce nitrergic activity, so molecules aiming to decrease NO production such as NO synthase (NOS) inhibitors might be candidates. Here, I critically review advances in research on these emerging molecules which hold promise although a note of caution is required on account of their potential neurotoxicity and narrow therapeutic window.

Keywords: Nitric oxide, nitric oxide inhibitors, schizophrenia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 29 August, 2016
Page: [2692 - 2705]
Pages: 14
DOI: 10.2174/0929867323666160812151054
Price: $65

Article Metrics

PDF: 45